APA (7th ed.) Citation

Huwyler, F., Kunz, R., Bacher, U., Hoffmann, M., Novak, U., Daskalakis, M., . . . Pabst, T. (2023). Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell Lymphoma. Cancers, 15(7), 2091. https://doi.org/10.3390/cancers15072091

Chicago Style (17th ed.) Citation

Huwyler, Fabrizio, Rebekka Kunz, Ulrike Bacher, Michèle Hoffmann, Urban Novak, Michael Daskalakis, Yara Banz, and Thomas Pabst. "Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell Lymphoma." Cancers 15, no. 7 (2023): 2091. https://doi.org/10.3390/cancers15072091.

MLA (9th ed.) Citation

Huwyler, Fabrizio, et al. "Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell Lymphoma." Cancers, vol. 15, no. 7, 2023, p. 2091, https://doi.org/10.3390/cancers15072091.